Navigation Links
Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta

MOSCOW, April 4, 2017 /PRNewswire/ --

Hepatera LLC and its development partner MYR GmbH today announced the completion of recruitment for MYR 202 and 203 clinical trials, a Phase 2b program investigating Myrcudex B in chronic hepatitis delta infection. 180 subjects have been enrolled in 20 centers in Russia and Germany.

Maxwell Biotech Venture Fund Logo
Maxwell Biotech Venture Fund Logo


"We are pleased to participate in the MYR 202 trial and look forward to results of this world's largest study in this severe unmet medical need," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR's Clinical Advisory Board.

"We are thankful for the enthusiastic collaboration of the participating centers, which has allowed us to meet the recruitment goals within the planed period," commented Dr. Dmitry Popov, Managing Partner of Maxwell Biotech Fund. "The interim results of MYR 202 will be available by the end of 2017."

About Myrcludex B 

Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.

About Hepatera 

The main activity of Hepatera Ltd. is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. Myrcludex B is developed by the company in cooperation with the biotechnology company MYR, GmbH (Germany).

About MYR GmbH 

MYR GmbH is a clinical stage biotechnology company focused on drugs for treatment of chronic hepatitis B and D virus infections. The company was founded in 2010 and is based in Burgwedel, Germany. Myr GmbH is received investments from Maxwell Biotech Venture Fund and High-Tech Gründerfonds (HTGF).

About Maxwell Biotech Venture Fund 

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The Fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development; four thereof are in Phase 2.

SOURCE Maxwell Biotech Venture Fund
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Start of Phase 2b Clinical Trial of Myrcludex B
2. Separation Systems for Commercial Biotechnology
3. Research Reports Coverage on Biotech Stocks -- Agenus, Intrexon, Progenics Pharma, and Concordia
4. Agricultural Biotechnology - Emerging Technologies & Global Markets - Driving Forces, Market Applications, Industry Structure & Competitive Dynamics - Research and Markets
5. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
6. On World Tuberculosis Day 2017, American/Russian biotech partnership announces positive trial results for a new treatment of TB
7. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
8. Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus
9. Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care
10. Three Day Biotechnology for the Non-Biotechnologist Course (London, United Kingdom - September 27-28-29, 2017) - Research and Markets
11. Festo Introduces at Interphex a New Family of Sanitary/Automated Ball, Angle Seat, and Pinch Valves for the Pharma and Biotech Industries
Post Your Comments:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... recipients of 13 prestigious awards honoring scientists who have made ... in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
(Date:10/7/2017)... Arizona (PRWEB) , ... October ... ... 15 years’ experience providing advanced instruments and applications consulting for microscopy and ... in-house expertise in application consulting, Nanoscience Analytical offers a broad range of ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture Network ... at their fourth annual Conference where founders, investors, innovative practitioners and collaborators are ... pitch competition showcasing early stage digital health and med tech companies. , This ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):